Skip to product information
1 of 1

Your Outdoor Setup Starts Here

Respiratory Test Kit Tyfast Flu A+B / COVID-19 Multiplex Rapid Test 25 Tests - ACT21001-25

Respiratory Test Kit Tyfast Flu A+B / COVID-19 Multiplex Rapid Test 25 Tests - ACT21001-25

review stars 1 Review

5% Sale

Only left!

image

Free Delivery

image

Limited Stocks

Regular price $286.99 Sale price $272.99
Shipping calculated at checkout.
Packaging

Quantity

View full details
SALE ENDS IN
07 HRS
23 MINS
28 SECS
DON'T MISS IT!

Popular Add on

$30.00

$28.99

$70.00

$66.99

Add-Ons Bundle

$30.00

$28.99

$70.00

$66.99

Bundle Offer

$100.00

$95.98

Recently Viewed

Features:

  • The CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test is only for in vitro diagnostic use under the Food and Drug Administration’s Emergency Use Authorization: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2
  • Product ships with minimum 90 days dating
  • The CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test is a lateral flow immunochromatographic assay intended for in vitro rapid, simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly from anterior nasal swab specimens of individuals with signs and symptoms of respiratory infection consistent with COVID-19 by their healthcare provider within the first five (5) days of symptom onset when tested at least twice over three days with at least 48 hours between tests
  • The test provides an efficient and accurate diagnostic solution in 10 mins, giving healthcare providers and communities a rapid and reliable way to prioritize their health
  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform moderate, high or waived complexity tests
  • This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
  • Results are for the simultaneous in vitro detection and differentiation of SARS-CoV-2, influenza A virus, and influenza B virus protein antigens, but do not differentiate, between SARS-CoV and SARS-CoV-2 viruses and are not intended to detect influenza C antigens
  • Positive results do not rule out bacterial infection or co-infection with other viruses
  • Negative results do not rule out influenza or SARS-CoV-2 infection, and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks


Product Specifications: